Clinical Research Directory

Inclusion Criteria: * Diagnosis: Confirmed undisturbed/intact unilateral tubal ectopic pregnancy (TEP) presenting with lower abdominal pain and absence of vaginal bleeding. * Pre-treatment beta-hCG Level: Baseline serum beta-human chorionic gonadotropin (beta-hCG) level of less than 3,500 IU/L. * Ectopic Mass Dimensions: Gestational mass with a maximum diameter of less than 3.5 cm measured on transvaginal ultrasonography (TVU). * Ultrasound Integrity: Absence of transvaginal ultrasound features indicating hemoperitoneum or active intraperitoneal bleeding. * Informed Consent: Willingness to comply with follow-up schedules and provision of written informed consent. Exclusion Criteria: * Disturbed Ectopic Pregnancy: Clinical, laboratory, or ultrasound evidence of tubal rupture, hemoperitoneum, or active intra-abdominal hemorrhage. * Elevated beta-hCG: Serum beta-hCG levels equal to or exceeding 3,500 IU/L at baseline. * Mass Size: Gestational mass diameter \> 3.5 cm. * Contraindications to Methotrexate or Letrozole: Known hypersensitivity or contraindications to therapy (e.g., active hepatic, renal, or hematological dysfunctions). * Non-compliance: Inability or unwillingness to comply with the serial post-treatment beta-hCG monitoring and follow-up protocol.